| Metric | Q2 2026 | Q2 2025 |
|---|---|---|
| Net income | -2.6 | -1.5 |
| EPS (diluted, $ a share) | $-2.60 | $-18.70 |
A dash means the filing did not report that period. Growth is not shown when either period was a loss. Figures from the filing's XBRL data.
10-Q filed with the SEC, NASDAQ: AEMD. Figures from the filing's XBRL data; summary written with AI assistance from the filing.
Aethlon Medical Inc: key numbers
- Share price
- $5.08Close, Nov 17
- Market cap
- $8.17M
- Shares outstanding
- 1.61MLatest SEC cover page
- Sector
- Industrial Applications and Services
- Industry
- Surgical & Medical Instruments & ApparatusSIC 3841
Today's reference numbers, updated daily. Not a valuation or a recommendation.
More from Aethlon Medical Inc
All →Aethlon Medical M&A Deal with North Immunology, Inc.
Aethlon Medical provided a status update on its pending merger with North Immunology, Inc., originally announced on September 17, 2026. The filing includes an updated investor presentation that North Immunology will use in meetings with investors regarding the transaction and a concurrent private placement.
- Counterparty
- North Immunology, Inc.
Aethlon Medical Financial Results
Aethlon Medical reported financial results for its fiscal second quarter ended September 30, 2026, highlighting a cash position of $6.5 million and a 77.2% increase in operating expenses due to merger-related professional fees. The company is currently progressing through a definitive merger agreement with North Immunology, Inc., which includes a contingent value right (CVR) for existing shareholders related to the legacy Hemopurifier business.
“We advanced our clinical program during the quarter. We treated the second participant in the third and final dosing cohort of our Phase 1 oncology study in Australia. We have treated eight patients across the three dosing cohorts to date and continue to pursue enrollment of one additional patient.”
James Frakes, CEO and CFO
Aethlon Medical Other 8-K Filing
Aethlon Medical filed an amendment to its Articles of Incorporation to increase the number of authorized shares of common stock from 20,000,000 to 200,000,000. The amendment was approved by stockholders at the 2026 Annual Meeting and became effective on October 7, 2026. This action increases the company's capacity for future equity issuances, though no shares were issued in this specific filing.
Aethlon Medical Shareholder Meeting
Aethlon Medical filed an amendment to its 2026 Annual Meeting results to clarify that Proposal No. 7, which sought to authorize 20 million shares of preferred stock, was not approved by stockholders. Although the proposal received a majority of votes cast, it failed to meet the required threshold of a majority of all outstanding shares. As a result, the company's Articles of Incorporation will not be amended to authorize the new class of preferred stock.
Aethlon Medical Shareholder Meeting
Aethlon Medical held its Annual Meeting of Stockholders on October 1, 2026, where shareholders elected five directors and ratified Haskell & White LLP as the independent auditor. Stockholders also approved an amendment to the 2020 Equity Incentive Plan to increase the authorized share pool by 100,000 shares and approved the potential issuance of shares related to warrants from a July 2026 offering.
Aethlon Medical Signs $150M M&A Deal with North Immunology, Inc.
Aethlon Medical (AEMD) has entered into a definitive agreement to acquire North Immunology in an all-stock merger transaction valued at a framework of $150 million for the target. Concurrent with the merger, North Immunology secured an oversubscribed $180 million private placement from a syndicate of healthcare investors to fund operations into 2028. The combined company will focus on advancing NOR-101, a bispecific antibody for atopic dermatitis, and will trade under the new ticker NRTX.
- Value
- $150M
- Counterparty
- North Immunology, Inc.